Inappropriate angiogenic response as a novel mechanism of duodenal ulceration and impaired healing

Digestive Diseases and Sciences

Volumn 56, Issue 10, 2011, Pages 2792-2801

  Deng, Xiaoming ^a,b   Xiong, Ximing ^a   Khomenko, Tetyana ^a,b   Sandor, Zsuzsanna ^a,c   Osapay, Klara ^a   Tolstanova, Ganna ^a,b   Shiloach, Joseph ^d   Chen, Longchuan ^a   Folkman, Judah ^e   Szabo, Sandor ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenic imbalance; Angiostatin; Duodenal ulcer; Endostatin; MMP2; TIMP 1; VEGF

Indexed keywords

ANGIOSTATIN; ENDOSTATIN; GELATINASE A; GELATINASE B; MERCAPTAMINE; PROPIONITRILE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DUODENUM MUCOSA; DUODENUM ULCER; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALING IMPAIRMENT; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

ANGIOSTATINS; ANIMALS; CYSTEAMINE; DISEASE MODELS, ANIMAL; DUODENAL ULCER; ENDOSTATINS; ENZYME INHIBITORS; FEMALE; INTESTINAL MUCOSA; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOVASCULARIZATION, PATHOLOGIC; NITRILES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 80054724523     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1753-4     Document Type: Article

References (49)

1. A Sonnenberg JE Everhart 1997 Health impact of peptic ulcer in the United States Am J Gastroenterol 92 614 620 9128309 1:STN:280:DyaK2s3nsVWlsw%3D%3D (Pubitemid 27184374)
2. P Bytzer PS Teglbjaerg 2001 Danish Ulcer Study Group. Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis-results from a randomized trial with 2-year follow-up Am J Gastroenterol 96 1409 1416 11374675 1:STN:280:DC%2BD3M3ptFykug%3D%3D
3. SX Kong HT Hatoum SZ Zhao NM Agrawal SG Geis 1998 Prevalence and cost of hospitalization for gastrointestinal complications related to peptic ulcers with bleeding or perforation: comparison of two national databases Am J Manag Care 4 399 409 10178500 1:STN:280:DyaK1c3hvVCgug%3D%3D (Pubitemid 28350796)
4. D Manuel A Cutler J Goldstein MB Fennerty K Brown 2007 Decreasing prevalence combined with increasing eradication of Helicobacter pylori infection in the United States has not resulted in fewer hospital admissions for peptic ulcer disease-related complications Aliment Pharmacol Ther 25 1423 1427 17539981 10.1111/j.1365-2036.2007.03340.x 1:STN:280:DC%2BD2szisl2juw%3D%3D (Pubitemid 46848893)
5. FK Chan WK Leung 2002 Peptic-ulcer disease Lancet 360 933 941 12354485 10.1016/S0140-6736(02)11030-0 (Pubitemid 35283840)
6. AP Jayaraj FI Tovey MR Lewin CG Clark 2000 Duodenal ulcer prevalence: experimental evidence for the possible role of dietary lipids J Gastroenterol Hepatol 15 610 616 10921413 10.1046/j.1440-1746.2000.02214.x 1:CAS:528:DC%2BD3cXltFOjtrY%3D (Pubitemid 30435710)
7. H Selye S Szabo 1973 Experimental model for production of perforating duodenal ulcers by cysteamine in the rat Nature 244 458 459 4582506 10.1038/244458a0 1:CAS:528:DyaE2cXjsVajtg%3D%3D
8. S Szabo ES Reynolds SH Unger 1982 Structure-activity relations between alkyl nucleophilic chemicals causing duodenal ulcer and adrenocortical necrosis J Pharmacol Exp Ther 223 68 76 7120129 1:CAS:528:DyaL38XmtV2rtbs%3D (Pubitemid 12033815)
9. S Fukuhara H Suzuki T Masaoka, et al. 2005 Enhanced ghrelin secretion in rats with cysteamine-induced duodenal ulcers Am J Physiol Gastrointest Liver Physiol 289 G138 G145 15778430 10.1152/ajpgi.00298.2004 1:CAS:528: DC%2BD2MXmvVeqs78%3D (Pubitemid 40944232)
10. Szabo S, Shing Y, Folkman MJ, et al. Angiogenesis and growth factors in ulcer healing. In: Fan Tai-Ping D, Kohn EC, eds. New Angiogenesis. Totowa, NJ: Humana Press, 2001;119-211.
11. J Folkman 2006 Angiogenesis Annu Rev Med 57 1 18 16409133 10.1146/annurev.med.57.121304.131306 1:CAS:528:DC%2BD28Xis1Cksrg%3D (Pubitemid 43261975)
12. NM Pandya NS Dhalla DD Santani 2006 Angiogenesis-a new target for future therapy Vascul Pharmacol 44 265 274 16545987 10.1016/j.vph.2006.01.005 1:CAS:528:DC%2BD28XktVyit7g%3D
13. A Vincze M Nagata Zs Sandor S Szabo 1996 ELISA and western blot studies with basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF) in experimental duodenal ulceration and healing Inflammopharmacology 4 261 265 10.1007/BF02731876 1:CAS:528:DyaK28XmsVGgsLo%3D (Pubitemid 26319905)
14. Szabo S, Vincze A, Sandor Zs, et al. Vascular approach to gastroduodenal ulceration: new studies with endothelins and VEGF. Dig Dis Sci. 1998;43(9 Suppl):40S-45S. (Pubitemid 28433948)
15. J Folkman S Szabo M Stovroff P McNeil W Li Y Shing 1991 Duodenal ulcer: discovery of a new mechanism and development of angiogenic therapy that accelerates healing Ann Surg 214 414 426 1719945 10.1097/00000658-199110000- 00006 1:STN:280:DyaK38%2FmtFansQ%3D%3D
16. S Szabo S Kusstatscher G Sakoulas Z Sandor A Vincze M Jadus 1995 Growth factors: new 'endogenous drugs' for ulcer healing Scand J Gastroenterol 30 15 18 10.3109/00365529509090262 1:CAS:528:DyaK2MXpsFGntr8%3D
17. X Deng S Szabo T Khomenko MR Jadus M Yoshida 2004 Gene therapy with naked DNA or adenoviral vector of VEGF or PDGF increases endogenous VEGF, PDGF and bFGF expression and accelerates chronic duodenal ulcer healing in rats J Pharmacol Exp Ther 311 982 988 15302893 10.1124/jpet.104.071464 1:CAS:528:DC%2BD2cXhtVKmtLzO (Pubitemid 39612702)
18. S Szabo A Vincze 2000 Growth factors in ulcer healing: lessons from recent studies J Physiol (Paris) 94 77 81 10.1016/S0928-4257(00)00146-7 1:CAS:528:DC%2BD3cXjtVyhtr8%3D (Pubitemid 30202857)
19. D Hanahan J Folkman 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 353 364 8756718 10.1016/S0092-8674(00)80108-7 1:CAS:528:DyaK28XltVSks7s%3D (Pubitemid 26272076)
20. MS O'Reilly L Holmgren Y Shing, et al. 1994 Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell 79 315 328 7525077 10.1016/0092-8674(94)90200-3 (Pubitemid 24324921)
21. MS O'Reilly T Boehm Y Shing, et al. 1997 Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 88 277 285 9008168 10.1016/S0092-8674(00)81848-6 (Pubitemid 28015876)
22. JH Distler A Hirth M Kurowska-Stolarska RE Gay S Gay O Distler 2003 Angiogenic and angiostatic factors in the molecular control of angiogenesis Q J Nucl Med 47 149 161 12897707 1:STN:280:DC%2BD3szmsVaisg%3D%3D (Pubitemid 37279152)
23. R Heljasvaara P Nyberg J Luostarinen, et al. 2005 Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases Exp Cell Res 307 292 304 15950618 10.1016/j.yexcr.2005. 03.021 1:CAS:528:DC%2BD2MXltFSqsbc%3D (Pubitemid 40799357)
24. L Claesson-Welsh M Welsh N Ito, et al. 1998 Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD Proc Natl Acad Sci USA 95 5579 5583 9576925 10.1073/pnas.95.10.5579 1:CAS:528:DyaK1cXjtFWktb8%3D (Pubitemid 28224137)
25. L Taddei P Chiarugi L Brogelli, et al. 1999 Inhibitory effect of full-length human endostatin on in vitro angiogenesis Biochem Biophys Res Commun 263 340 345 10491294 10.1006/bbrc.1999.1342 1:CAS:528:DyaK1MXlvFansLs%3D (Pubitemid 29467197)
26. JE Rundhaug 2005 Matrix metalloproteinases and angiogenesis J Cell Mol Med 9 267 285 15963249 10.1111/j.1582-4934.2005.tb00355.x 1:CAS:528: DC%2BD2sXlvFCluro%3D
27. Z Sandor XM Deng T Khomenko AS Tarnawski S Szabo 2006 Altered angiogenic balance in ulcerative colitis: a key to impaired healing? Biochem Biophys Res Commun 350 147 150 17011522 10.1016/j.bbrc.2006.09.021 1:CAS:528: DC%2BD28XhtVagsbbM (Pubitemid 44466584)
28. X Deng G Tolstanova T Khomenko, et al. 2009 Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine J Pharmacol Exp Ther 331 1071 1078 19762547 10.1124/jpet.109.158022 1:CAS:528:DC%2BD1MXhsFaqsLvK
29. E Smith R Hoffman 2005 Multiple fragments related to angiostatin and endostatin in fluid from venous leg ulcers Wound Rep Reg 13 148 157 10.1111/j.1067-1927.2005.130205.x (Pubitemid 40489864)
30. B Bucalo WH Eaglstein V Falanga 1993 Inhibition of cell proliferation by chronic wound fluid Wound Rep Reg 1 181 186 10.1046/j.1524-475X.1993.10308.x 1:STN:280:DC%2BD28jislSnuw%3D%3D
31. SL Drinkwater A Smith BM Sawyer KG Burnand 2002 Effect of venous ulcer exudates on angiogenesis in vitro Br J Surg 89 709 713 12027980 10.1046/j.1365-2168.2002.02085.x 1:STN:280:DC%2BD383ovVSqtg%3D%3D (Pubitemid 34595695)
32. SL Drinkwater KG Burnand R Ding A Smith 2003 Increased but ineffectual angiogenic drive in non-healing venous leg ulcers J Vasc Surg 38 1106 1112 14603223 10.1016/S0741-5214(03)01053-X (Pubitemid 37409649)
33. L Ma SN Elliott G Cirino A Buret LJ Ignarro JL Wallace 2001 Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release Proc Natl Acad Sci USA 98 6470 6475 11353854 10.1073/pnas.111150798 1:CAS:528:DC%2BD3MXktVWktL4%3D (Pubitemid 32488261)
34. M Kato H Wang V Kainulainen, et al. 1998 Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2 Nat Med 4 691 697 9623978 10.1038/nm0698-691 1:CAS:528:DyaK1cXjsFyntrg%3D (Pubitemid 28274669)
35. J Sottile 2004 Regulation of angiogenesis by extracellular matrix Biochim Biophys Acta 1654 13 22 14984764 1:CAS:528:DC%2BD2cXhsVKhsb4%3D (Pubitemid 38230928)
36. M Weckroth A Vaheri J Lauharanta T Sorsa YT Konttinen 1996 Matrix metalloproteinases, gelatinase and collagenase, in chronic leg ulcers J Invest Dermatol 106 1119 1124 8618050 10.1111/1523-1747.ep12340167 1:CAS:528: DyaK28Xjs1Shurc%3D (Pubitemid 26155102)
37. G Lauer S Sollberg M Cole, et al. 2000 Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds J Invest Dermatol 115 12 18 10886501 10.1046/j.1523-1747.2000.00036.x 1:CAS:528:DC%2BD3cXlt1Whu7o%3D (Pubitemid 30470185)
38. W Bloch K Huggel T Sasaki, et al. 2000 The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing FASEB J 14 2373 2376 11024009 1:CAS:528:DC%2BD3MXht1Sntr0%3D
39. T Boehm J Folkman T Browder MS O'Reilly 1997 Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature 390 404 407 9389480 10.1038/37126 1:CAS:528:DyaK2sXns12rsL8%3D (Pubitemid 28027321)
40. N Yamaguchi B Anand-Apte M Lee, et al. 1999 Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding EMBO J 18 4414 4423 10449407 10.1093/emboj/18.16.4414 1:CAS:528:DyaK1MXlslWgu7g%3D (Pubitemid 29391251)
41. NJ McDonald WY Shivers DL Narum, et al. 2001 Endostatin binds tropomyosin: a potential modulator of the antitumor activity of endostatin J Biol Chem 276 25190 25196 10.1074/jbc.M100743200
42. B Mwaura B Mahendran N Hynes, et al. 2006 The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers Eur J Vasc Endovasc Surg 31 306 310 16169261 10.1016/j.ejvs.2005.08.007 1:STN:280:DC%2BD287htlCqsw%3D%3D (Pubitemid 43263515)
43. S Swarnakar A Mishra K Ganguly AV Sharma 2007 Matrix metalloproteinase-9 activity and expression is reduced by melatonin during prevention of ethanol-induced gastric ulcer in mice J Pineal Res 43 56 64 17614836 10.1111/j.1600-079X.2007.00443.x 1:CAS:528:DC%2BD2sXosFCjt7Y%3D (Pubitemid 47035222)
44. JD Mott Z Werb 2004 Regulation of matrix biology by matrix metalloproteinases Curr Opin Cell Biol 16 558 564 15363807 10.1016/j.ceb.2004. 07.010 1:CAS:528:DC%2BD2cXnsFGktLc%3D (Pubitemid 39201241)
45. LA Cornelius LC Nehring E Harding, et al. 1998 Matrix metalloproteinases generate angiostatin: effects on neovascularization J Immunol 161 6845 6852 9862716 1:CAS:528:DyaK1cXotFWqtbk%3D (Pubitemid 28562229)
46. M Ferreras U Felbor T Lenhard BR Olsen J Delaissé 2000 Generation and degradation of human endostatin proteins by various proteinases FEBS Lett 486 247 251 11119712 10.1016/S0014-5793(00)02249-3 1:CAS:528: DC%2BD3cXovFGru7s%3D
47. UW Nilsson C Dabrosin 2006 Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo Cancer Res 66 4789 4794 16651433 10.1158/0008-5472.CAN-05-4012 1:CAS:528: DC%2BD28XjvF2ktrc%3D
48. A Ito H Nagase Y Mori 1989 Characterization of metalloproteinases in rat gastric tissues with acetic acid-induced ulcers Scand J Gastroenterol Suppl 162 146 149 2595286 10.3109/00365528909091147 1:STN:280:DyaK3c%2FosVertQ%3D%3D (Pubitemid 19220343)
49. S Kobayashi N Nakajima Y Ito M Moriyama 2010 Effects of lansoprazole on the expression of VEGF and cellular proliferation in a rat model of acetic acid-induced gastric ulcer J Gastroenterol 45 846 858 20333532 10.1007/s00535-010-0224-6 1:CAS:528:DC%2BC3cXhtVSmtbvL